Neuropathy is major source of chronic pain that can be caused by mechanically or chemically induced nerve injury. Previous work in a rat model of neuropathic pain demonstrated that bilateral formalin injection into the hind paws produced mechanical hypersensitivity (allodynia) and depressed responding for intracranial self-stimulation (ICSS). To determine whether neuropathy alters dopamine receptor responsiveness in mesolimbic brain regions, we examined dopamine D1-like and D2-like receptor (D1/2R) signaling and expression in male rats 14 days after bilateral intraplantar formalin injections into both rear paws. D2R-mediated Gprotein activation and expression of the D2R long, but not short, isoform were reduced in nucleus accumbens (NAc) core, but not in NAc shell, caudate-putamen (CPu) or ventral tegmental area (VTA) of formalin-compared to saline-treated rats. In addition, D1R-stimulated adenylyl cyclase (AC) activity was also reduced in NAc core, but not in NAc shell or prefrontal cortex, of formalin-treated rats, whereas D1R expression was unaffected. Expression of other proteins involved in dopamine neurotransmission, including dopamine uptake transporter (DAT) and tyrosine hydroxylase (TH), were unaffected by formalin treatment. In behavioral tests, the effects of D2R agonists on ICSS were attenuated in formalin-treated rats, whereas the effects of D1R agonists were unchanged. These results indicate that intraplantar formalin as a model of chemically induced neuropathy produces attenuation of highly specific DA receptor signaling processes in NAc core of male rats.
INTRODUCTION
The mesolimbic dopamine (DA) system consists of dopaminergic neurons that project from the ventral tegmental area (VTA) in midbrain to forebrain targets that include the nucleus accumbens (NAc) core and shell (Ikemoto et al., 2015; Sesack and Grace, 2010) . Postsynaptic neurons in NAc consist primarily of two broad populations defined in part by their expression of either D1-like or D2-like DA receptors (D1R and D2R, respectively) (Beaulieu and Gainetdinov, 2011) . Dopaminergic transmission between mesolimbic DA neurons and their postsynaptic NAc targets is known to play a major role in the neural representation of rewarding stimuli and the expression of motivated behavior, and a growing body of evidence suggests that pain states can impair that signaling (Mitsi and Zachariou, 2016; Taylor et al., 2016; Watanabe and Narita, 2018) . As one example, we evaluated effects of intraperitoneal injection of dilute lactic acid (IP acid) in rats as an acute visceral noxious stimulus on both in vivo microdialysis measures of NAc core DA levels and intracranial self-stimulation (ICSS) as a positively reinforced operant behavior dependent on mesolimbic DA signaling (Leitl et al., 2014a) . IP acid produced a concentration-dependent decrease in both NAc DA levels and ICSS, and both effects could be blocked by clinically effective analgesics, including morphine and ketoprofen. Manipulations often used in rodent models of chronic pain produce more subtle effects on mesolimbic DA signaling (Mitsi and Zachariou, 2016; Taylor et al., 2016; Watanabe and Narita, 2018) and
behavior (Negus, 2019) . However, we found previously that intraplantar (Ipl) injection of formalin served as a model of chemically induced neuropathy in rats that produced sustained changes in both a conventional metric of pain-related behavior (hypersensitive paw withdrawal from tactile stimuli delivered via von Frey filaments) as well as small but statistically significant and sustained depression of ICSS suggestive of sustained depression of mesolimbic DA signaling (Leitl and Negus, 2016; Leitl et al., 2014a) . Microdialysis assessment of extracellular DA levels as a measure of DA signaling is best suited to within-subject evaluation of relatively transient changes in DA release over the course of minutes to hours, for example in studies with acute noxious or antinociceptive stimuli (Leitl et al., 2014a; Navratilova et al., 2012) . More sustained changes in DA signaling, such as that potentially produced by chronic pain states, might be expected to alter more durable components of DA signaling, such as the activity or expression of DA receptors. Accordingly, the present study evaluated effects of Ipl formalin as a chronic neuropathic-pain stimulus on function and expression of DA receptors and related biomarkers of DA signaling.
Pain states have been associated with alterations in striatal dopamine D2R in both preclinical animal models and human imaging studies (Mitsi and Zachariou, 2016; Taylor et al., 2016) . Human imaging studies have shown either increased or decreased striatal D2R receptor binding potentials using positron emission tomography in various pain states (Martikainen et al., 2018; Martikainen et al., 2015) ; however, these results could be due to changes in dopamine (DA) occupancy or altered D2R Bmax levels (or both). In addition, the direction and magnitude of changes in D2R binding potentials can rapidly change in chronic pain patients in response to acute pain challenge (DaSilva et al., 2017; Martikainen et al., 2018) . Moreover, human genetic studies have shown that polymorphism in the Drd2 gene is associated with baseline pain sensitivity, analgesic response to transcranial magnetic stimulation and likelihood of developing post-injury neuropathic pain (Jaaskelainen et al., 2014) . Altogether, these findings suggest important roles for D2R function in the brain in human responses to painful stimuli.
Preclinical studies generally indicate decreases in D2R levels following chronic pain models in rodents, whereas synaptic DA levels have been reported to either increase or decrease.
For example, dopaminergic neuronal burst firing in VTA and intra-NAc DA levels were increased, whereas D2R and tyrosine hydroxylase (TH) protein levels were decreased, two weeks after spared nerve injury (SNI) in rats (Sagheddu et al., 2015) . Moreover, both D2R and D1R mRNA levels were decreased in NAc 28 days after surgery in this same SNI model (Chang et al., 2014) . In contrast, NAc DA levels were decreased two weeks after peripheral nerve injury in mice (Taylor et al., 2014) . Furthermore, decreased DA and increased dopamine transporter (DAT) levels were seen in NAc of rats two weeks after SNI (Wu et al., 2014 and D1R signaling in NAc core, so ICSS studies were then conducted to determine whether these changes were associated with altered ability of D2-and D1-like agonists to affect ICSS responding (Lazenka et al., 2016) .
MATERIALS AND METHODS

Experimental Subjects
Adult male Sprague-Dawley rats (ENVIGO, Frederick, MD) were used for these studies.
All rats had ad libitum access to food and water and were housed individually at Virginia 
Dissections.
Fourteen days after Ipl treatment with formalin or saline, rats were euthanized by rapid decapitation, and brains were dissected using anatomical landmarks similar to those described previously in mice (Lazenka et al., 2017b; Wiebelhaus et al., 2015) with necessary modification. The prefrontal cortex was dissected by making a cut at the posterior extent of the anterior olfactory nucleus after which the olfactory nuclei were removed. This sample included frontal association, primary and secondary motor, anterior cingulate, prelimbic and orbital frontal cortices. A cut was then made anterior to the optic chiasm, producing a slice that included both the caudate-putamen and NAc. The nucleus accumbens was isolated by removing the cortex ventrally, the septum and nucleus of the horizontal limb of the diagonal band medially and separating the remaining tissue inferior to the caudate-putamen. The NAc core was separated from the NAc shell by removing tissue ventral, lateral and medial to the anterior commissure (shell) such that a tear-shaped structure tapering at the lateral ventricle superiorly and containing the anterior commissure was left (core). The remaining caudateputamen was isolated by removing the corpus callosum and surrounding cortex. To dissect the VTA, slice was taken by first cutting immediately anterior to the mammillary bodies and a second cut was made anterior to the middle cerebellar peduncle, at the midpoint of the cerebral peduncles. From this slice, the interpeduncular nucleus/mammillary bodies, located ventrally; the substantia nigra, located laterally; and the interfascicular nucleus, located medially were removed. The remaining region ventral to the red nucleus was dissected and comprised primarily the VTA. All dissected tissue was stored at -80°C until use.
Membrane preparation.
Membranes were prepared from dissected brain regions as previously described . Briefly, tissue was thawed in membrane buffer (Tris-HCl, pH 7.4, 3 mM MgCl2, 1 mM EGTA), homogenized and centrifuged at 40,000 x g for 10 min. The pellet was collected and homogenized in assay buffer (Tris-HCl, pH 7.4, 3 mM MgCl2, 0.1 mM EGTA, 100 mM NaCl) and protein was determined by the Bradford method.
[ 35 S]GTPgS binding. Membranes were pretreated with adenosine deaminase (AD)
for 15 min at 30°C prior to assay. [ 35 S]GTPgS binding was conducted essentially as previously described . Briefly, membranes (3-6 µg protein were then incubated with varying concentrations of quinelorane (D2-like agonist) or CP55,940 (cannabinoid agonist), 30
µM GDP, and 0.1 nM [ 35 S] GTPgS in assay buffer containing 0.1% BSA, for 2 hr at 30°C in a 0.5 ml total volume. Basal binding was assessed without agonist and nonspecific binding was measured with 20 µM unlabeled GTPgS. The assay was terminated by filtration through GF/B glass fiber filters, followed by 3 washes with ice-cold Tris buffer. Bound radioactivity was determined by liquid scintillation spectrophotometry.
Adenylyl cyclase activity.
Adenylyl cyclase assays were performed as previously described (Sim-Selley et al., 2011) with minor modifications. Membranes (20 µg protein) were pretreated with AD as above and incubated with varying concentrations of SKF82958 (D1-like agonist) or CGS21689 (A2a agonist) in assay buffer containing 0.1% BSA, 50 µM ATP, 50 µM GTP, 0.2 mM DTT, 0.2 mM papaverine, 5 mM phosphocreatine, and 20 U/ml creatine phosphokinase for 15 min at 30°C. The incubation was terminated by addition of ELISA sample diluent, and cAMP was quantified using a cAMP ELISA kit (Arbor Assays, Ann Arbor, MI).
Data analysis for in vitro functional assays.
Data are reported as mean values ± SEM of 5-6 rats per group with samples assayed in duplicate. Concentration-effect curves were subjected to non-linear regression analysis to determine Emax and EC50 values. To control for day-to-day interassay variability, Emax values in both groups were also normalized to the salinetreated value on each day of the experiment. Significance of agonist-stimulation and formalin treatment was determined by two-way ANOVA with agonist concentration and formalin-versussaline treatment as the main factors. Differences in Emax and EC50 values between groups were determined by the two-tailed Student's t-test. All curve-fitting and statistical analysis was conducted using Prism software (GraphPad, San Diego, CA).
Protein quantification by immunoblot.
Dissections.
Fourteen days after Ipl treatment with formalin or saline, rats were euthanized by rapid decapitation, and whole brains were frozen in isopentane at -30 °C and shipped frozen on dry ice to McLean Hospital for evaluation using methods similar to those described previously (Der-Avakian et al., 2017; Yap et al., 2015) . Briefly, frozen brains were coronally sectioned on a cryostat (HM 505 E; Microm; Walldorf, Germany) until the following regions were exposed: NAc Core (Bregma 2.52mm), NAc Shell (Bregma 2.52mm), and VTA (Bregma −5.04mm), based on the atlas of Paxinos and Watson. Bilateral tissue punches 1-1.5 mm in length were taken with a 1 mm internal diameter corer (Fine Science Tools; Foster City, CA) and placed in Eppendorf tubes kept on dry ice and then stored at −80° C. After removal of the tissue cores, coronal sections (30 μM) of the exposed face of the brain were taken and Nissl stained with cresyl violet for histological analysis of placements. Only the rats in which the tissue punches were targeted appropriately were included in analyses.
Immunoblotting.
Tissue was sonicated in 1% sodium dodecyl sulfate (SDS) to dissociate membranes. Total protein concentrations in samples were determined using the Bio-Rad DC Protein Assay kit (Hercules, CA), and the concentration of each sample was adjusted to 2.0 mg/ml protein. Cell lysates were heated to 70°C for 10 min before polyacrylamide gel electrophoresis. Denatured protein (10-20 µg) was loaded per lane on 4-12% Bis-Tris Gels (Invitrogen). Protein was transferred onto PVDF membrane. Membranes were stained with Ponceau S then rapidly imaged for total protein as loading control/normalization before blocking for 2 hours at RT with 5% nonfat dry milk in TBS-T with 0.02% Tween 20, then incubated with mouse monoclonal anti-D2R (1:250; Santa Cruz SC-5303) in TBS-T overnight at 4C to detect long and short forms of D2R at 51 and 48kDa. Other primary antibodies included pTH (cell Signaling S3; 1; 1:1000); TH (Millipore/Sigma AB152; 1:40000); DAT (Millipore AB2231; 1:20000); D1R (Santa Cruz SC 14001; 1:250).
Data analysis.
Data are reported as mean values ± SEM of 5-6 rats per group.
Immunoblots were analyzed by normalization of optical densities of immunoreactive protein to Ponceau stain, and then normalization of both groups to the saline condition. Significant differences were determined using Student's t-test, conducted with Prism software. For all studies, rats received bilateral Ipl injections of 5% formalin (100 ul in each hind paw) or saline, as described previously (Leitl et al., 2014b) . For behavioral studies, quinpirole and SKF82958 were administered by intraperitioneal (i.p.) injection, and drug doses are expressed in units of the salt form above.
In vivo assessment of intracranial self-stimulation (ICSS)
Drugs for in vivo delivery
Surgery.
Rats were anesthetized with isoflurane (3% in oxygen; Webster Veterinary, Phoenix, AZ, USA) until unresponsive to toe-pinch prior to implantation of stainless steel electrodes (Plastics One, Roanoke, VA, USA). The cathode, which was 0.25 mm in diameter and covered with polyamide insulation except at the flattened tip, was implanted utilizing a stereotactic method into the left medial forebrain bundle (MFB) at the level of the lateral hypothalamus using previously published coordinates (2.8 mm posterior to bregma, 1.7 mm lateral to the midsagittal suture, and 8.8 mm ventral to the skull) (Leitl et al., 2014b) . Three screws were placed in the skull, and the anode (0.125 mm diameter, un-insulated) was wrapped around one of the screws to act as a ground. Dental acrylic was used to secure the electrode to the screws and skull. Ketoprofen (5 mg/kg) was administered as a postoperative analgesic immediately and 24 hrs following surgery. Animals were allowed to recover for at least one week before ICSS training.
Apparatus. Operant conditioning chambers consisted of sound-attenuating boxes
containing modular acrylic and metal test chambers (29.2 cm X 30.5 cm X 24.1 cm) (Med Associates, St. Albans, VT). Each chamber had a response lever (4.5 cm wide, 2.0 cm deep, 3.0 cm above the floor), a 2-watt house light, three stimulus lights (red, yellow and green) centered 7.6 cm above the lever, and an ICSS stimulator. Bipolar cables routed through a swivelcommutator (Model SL2C, Plastics One) connected the stimulator to the electrode. MED-PC IV computer software controlled all programming parameters and data collection (Med Associates).
Training.
The behavioral procedure was similar to that described previously for studies with formalin (Leitl and Negus, 2016; Leitl et al., 2014b) and with direct dopamine agonists (Lazenka et al., 2017a; Lazenka et al., 2016) . A house light was illuminated during behavioral sessions, and lever-press responding under a fixed-ratio 1 (FR1) schedule produced delivery of a 0.5 s train of square-wave cathodal pulses (0.1 ms per pulse) via the intracranial electrode. During brain stimulation, the stimulus lights over the lever were illuminated, and responding had no scheduled consequences. During initial 60 min training sessions, stimulation intensity was set at 150 µA, and stimulation frequency was set at 158 Hz. Stimulation intensity was then individually manipulated in each rat to identify an intensity that maintained reinforcement rates >30 stimulations/min (range of 120 µA-215 µA for rats in this study). Once an appropriate intensity was identified, changes in frequency were introduced during sessions consisting of three consecutive 10 min components, each of which contained 10 consecutive 60 s trials. The stimulation frequency was 158 Hz for the first trial of each component, and frequency decreased in 0.05 log unit steps during the subsequent nine trials to a final frequency of 56 Hz.
Each trial began with a 10 s time-out period, during which responding had no scheduled consequences, and five non-contingent stimulations at the designated frequency were delivered at 1 s intervals during the last 5 s of the time out. During the remaining 50 s of each trial, responding produced both intracranial stimulation at the designated frequency and illumination of the lever lights under an FR1 schedule as described above. ICSS performance was considered to be stable when frequency-rate curves were not statistically different over three consecutive days of training as indicated by lack of a significant effect of 'day' in a two-way analysis of variance (ANOVA) with day and frequency as the main effect variables (see Data Analysis below). All training was completed within six weeks of surgery. data were then averaged across rats to yield mean baseline and test frequency-rate curves for each manipulation. Results were compared by repeated measures two-way ANOVA with ICSS frequency as a within-subject factor and either Ipl treatment (between-subjects factor) or dopamine agonist dose (within-subjects factor) as the second factor. A significant ANOVA was followed by the Holm-Sidak post-hoc test, and the criterion for significance was p < .05.
To provide an additional summary measure of ICSS performance, the total number of stimulations per component was determined across all 10 frequency trials of each component. Stimulations was calculated as (mean total stimulations during a component/mean total stimulations during baseline components) x 100. These data were then averaged across rats.
Baseline data in formalin-and saline-treatment groups on a given day were compared by t-test.
Drug effects in formalin-and saline-treatment groups on a given day were compared by two-way mixed ANOVA with dose as a within-subjects factor and Ipl treatment as a between-subjects factor. A significant ANOVA was followed by the Bonferroni Holm-Sidak post-hoc test, and the criterion for significance was p < 0.05. All statistical analyses were conducted with Prism software. Figure 1A) . Concentration-effect curves of quinelorane-stimulated [ 35 S]GTPgS binding were examined in NAc core versus shell. Results in NAc core showed decreased D2Rstimulated activity in formalin-relative to saline-treated-rats, as confirmed by two-way ANOVA, which revealed a main effect of formalin treatment ( Figure 1A) . Curve-fitting analysis revealed trends toward a significant decrease in Emax (t(8) = 1.995, p = 0.081) and increase in log EC50
RESULTS
Formalin treatment selectively attenuates
to each corresponding value in saline-treated rats revealed a significant decrease [t(8) = 2.514, p = 0.036] in formalin-compared to saline-treated rats (Table 1) .
To determine whether the formalin-induced decrease in G-protein activation was homologous to D2-like receptors, activity of the CB1 cannabinoid receptor, another Gi/o-coupled receptor that has overlapping localization with D2 R in NAc (Pickel et al., 2006) , was examined.
In contrast to results with the D2-like agonist quinelorane, G-protein activation by the cannabinoid agonist CP55,940 was unaffected by formalin treatment, as indicated by two-way ANOVA ( Figure 1B ). Emax and log EC50 values of CP55,940 did not differ between formalinand saline-treated rats (Table 1) .
Formalin treatment did not alter D2R-mediated G-protein activation in NAc shell, as indicated by two-way ANOVA ( Figure 1C ). Quinelorane Emax and log EC50 values did not differ between formalin-and saline-treated rats (Table 1) . Similarly, CP55,940-stimulated G-protein activation in NAc shell was unaffected by formalin treatment (data not shown). Emax and log EC50 values of CP55,940 did not differ between formalin-and saline-treated rats (Table 1) .
D2-like receptor-stimulated G-protein activation was also assessed in VTA and CPu (Supplemental Figure 2) . Results in VTA showed low and variable stimulation of [ 35 S]GTPgS binding by quinelorane, which did not differ between saline-and formalin-treated rats, as indicated by two-way ANOVA. Accordingly, quinelorane Emax and log EC50 values in VTA did not differ between groups (Table 1) . Quinelorane produced more robust stimulation in CPu, but there was no effect of formalin treatment, as indicated by two-way ANOVA. Quinelorane Emax and log EC50 values in CPu did not differ between saline-and formalin-treated rats (Table 1) .
Altogether, these results indicate that Ipl formalin treatment attenuated D2R-mediated G-protein activation in NAc core, but not in NAc shell, CPu or VTA, without affecting CB1 cannabinoid receptor-mediated G-protein activation.
Formalin treatment selectively attenuates D1-like receptor-mediated AC activation in
NAc core.
The effect of Ipl formalin treatment on G-protein signaling by dopamine D1-like receptors was determined with SKF82958-stimulated AC activity in membranes prepared from NAc core and shell. Basal AC activity varied among regions but was unaffected by formalin treatment, as indicated by two-way ANOVA (Supplemental Figure 1B) . Concentration-effect curves of SKF82958-stimulated AC activity were examined in NAc core versus shell. Results in NAc core showed decreased D1R-stimulated activity in formalin-relative to saline-treated rats, as confirmed by two-way ANOVA, which showed a main effect of formalin treatment ( Figure   2A ). Curve-fitting analysis revealed a significant decrease in both Emax [t(12) = 2.308, p = 0.039] and normalized Emax values [t(12) = 2.869, p = 0.014] of SKF82958 in formalincompared to saline-treated rats, with no difference in log EC50 values (Table 2 ). In contrast, AC activation in NAc core by the adenosine A2a agonist CGS21680 was unaffected by formalin treatment, as indicated by two-way ANOVA ( Figure 2B ). Emax and log EC50 values of CGS21680 did not differ between formalin-and saline-treated rats ( Table 2) .
Formalin treatment did not alter D1R-mediated AC activation in NAc shell, as indicated by two-way ANOVA ( Figure 2C ). SKF82958 Emax and log EC50 values did not differ between formalin-and saline-treated rats ( Table 2) . CGS21680-stimulated AC activity was minimal (Emax ≤ 10%) in NAc shell and showed concentration-dependent stimulation only in 4 of the 5 sample pairs, so 4 samples per group were included in the analysis (data not shown). Emax and log EC50 values of CGS21680 did not differ between formalin-and saline-treated rats (Table 2) .
Because D1 and A2a receptors are the major Gs/olf-coupled receptors driving AC activation in each of the two distinct populations of striatal medium spiny neurons, the effect of formalin on the ratio of maximal AC activation by each receptor was determined. The ratio of D1/A2astimulated AC activity was decreased by ~41% in NAc core of formalin-relative to salinetreated rats (1.11 ± 0.16 versus 1.87 ± 0.28, respectively; [t(12) = 2.430, p = 0.032]). In contrast, formalin treatment did not affect the ratio of D1/A2a-stimulated AC activity in NAc shell (2.79 ± 0.46 versus 2.49 ± 0.20 in formalin-and saline-treated rats, respectively).
Formalin treatment also did not alter D1R-mediated AC activation in the prefrontal cortex (PFC), a dopaminergic terminal field region that is enriched in D1-like receptors (Herve et al., 1992 ) (Supplemental Figure 3) . SKF82958 stimulated AC activity in a concentration-dependent manner, but there was no effect of formalin treatment, as indicated by two-way ANOVA.
Neither Emax nor log EC50 values of SKF82958 differed between saline-and formalin-treated rats (Table 2) . Taken together, these results indicate that formalin treatment attenuated D1R-mediated AC activation in NAc core, but not in NAc shell or PFC, without significantly altering adenosine A2a receptor-mediated AC activation. Moreover, the ratio of D1:A2a-stimulated AC activity was significantly decreased in NAc core but not shell.
Formalin treatment selectively decreases D2L receptor protein levels in NAc core.
The receptor function experiments described above showed decreases in both D2-like receptor-mediated G-protein activation and D1-like receptor-mediated AC activation in NAc core but not shell of formalin-treated rats. Because decreased functional activity could be due to decreased receptor levels, reduced coupling between each receptor and its cognate G-protein or both, D2R and D1R protein levels were determined by immunoblot analysis of NAc core and shell. Results in NAc core ( Figure 3A, C and E; Supplemental Figures 3 and 4) showed a ~17% decrease in D2R long isoform (D2L) immunoreactivity in formalin-compared to saline-treated rats [t(10) = 2.363, p = 0.020], without any difference in D2R short isoform (D2S) levels.
In contrast to results in NAc core, no differences in either D2L or D2S receptor levels were seen in NAc shell ( Figure 3B, D and F) . D1R immunoreactivity also did not differ between saline-and formalin-treated rats in either NAc core or shell (Supplemental Figures 6 and 7) .
Likewise, D2L, D2S and D1 receptor immunoreactivity did not differ between formalin-and saline-treated rats in VTA or PFC (data not shown). Furthermore, immunoblot analysis of other proteins important in the regulation of dopamine neurotransmission, including DAT tyrosine hydroxylase (TH) and phospho-TH, also showed no differences between formalin-and salinetreated rats in NAc core or shell, VTA or PFC (data not shown). Altogether, these results indicate that formalin treatment selectively decreased D2LR protein in the NAc core without affecting other proteins directly involved in dopamine neurotransmission.
Formalin treatment attenuates modulation of ICSS responding by D2 but not D1 receptor activation.
Under baseline conditions, MFB stimulation maintained a frequency-dependent increase in reinforcement rates. The mean ± SEM maximum control rate for all rats in the study was 53 ± 1.9 stimulations per trial, and the mean ± SEM baseline number of stimulations per component was 224 ± 11.5. There were no differences across groups in either baseline ICSS or in drug effects on ICSS on Day 1, before formalin or saline treatment (data not shown). Figure 4 shows that there was also no difference in baseline ICSS performance on Day 16, 14 days after formalin or saline treatment. Figure 5 shows effects of quinpirole and SKF82958 on Day 16 in each group. Quinpirole produced dose-dependent rightward/downward shifts in the ICSS frequencyrate curves in both groups; however, quinpirole was less potent to decrease the number of stimulations per component in the formalin-treated group than in the saline-treated group.
SKF82958 produced a mixed profile of ICSS facilitation and ICSS depression in both groups. In particular, a dose of 0.1 mg/kg SKF82958 facilitated ICSS for at least one brain-stimulation frequency in both groups, and a higher dose of 0.32 mg/kg SKF82958 decreased ICSS for at least two brain-stimulation frequencies in both groups. There were no significant differences between formalin-and saline-treated groups in SKF82958 effects on the number of stimulations per component.
DISCUSSION
Summary of major findings.
The present study examined the effects of bilateral Ipl formalin, a method often used to model of chronic pain in humans, on DA receptor expression and signaling in the mesolimbic DA system and on modulation of ICSS behavior by D1-like and D2-like receptor agonists. In agreement with previous studies, the overall results of this study indicate that chronic pain manipulations can modulate DA signaling in the mesolimbic system, including changes in D2like receptor expression in NAc. Moreover, three major novel findings were revealed. First, selective reductions in both D1R and D2R-mediated G-protein signaling were demonstrated within the NAc. These effects were receptor-homologous as suggested by the finding that formalin treatment did not significantly affect activity of the Gs/olf-coupled adenosine A2a receptor or the Gi/o-coupled cannabinoid CB1 receptor. Second, these effects, along with decreased D2LR protein, were seen in NAc core but not the shell. Further, decreased D2R expression was specific for the long but not short isoform of the D2R, indicating reduced expression of the post-synaptic D2R population. Third, the decrease in NAc core D2R function and expression was associated with reduced potency of the D2-like agonist quinpirole to decrease positively reinforced operant responding in an ICSS procedure; however, behavioral effects of D1-like agonist on ICSS were not significantly altered. Altogether, this profile suggests that formalin-induced neuropathy can alter dopaminergic responsivity in the NAc core, with predominant downregulation of D2R function.
Formalin treatment attenuated DA receptor signaling and/or expression in NAc core.
Several previous preclinical and human functional imaging studies suggest a role for the NAc in both acute and chronic pain (Magnusson and Martin, 2002) (Becerra and Borsook, 2008 ) (Baliki et al., 2010; Baliki et al., 2013; Becerra et al., 2013; Chang et al., 2014; Schwartz et al., 2014) . The NAc can be divided into core and shell regions with evidence showing that each region responds differently to acute thermal pain in humans (Baliki et al., 2013) . The present study showed a decrease in quinelorane-stimulated G-protein activation and a specific decrease in the D2R receptor long isoform in the NAc core but not shell. In broad agreement with our results, other studies of neuropathic pain in rodents have shown opposing changes in neuron excitability of D2R expressing medium spiny neurons in the NAc core and shell (Ren et al., 2016) .
In addition to effects on D2R expression and activity, the current study also found that AC activity stimulated by the D1R-selective agonist SKF82958 was decreased in the NAc core but not shell. To our knowledge, this is the first study to show effects of neuropathy on D1R activity in the NAc or any changes in function in the D1R-expressing population of medium spiny neurons. D1R activation is capable of reversing pain-depressed behavior induced by intraperitoneal acid administration (Lazenka et al., 2017a) , and the present findings of reduced D1R activity in neuropathic rats suggest a potential for reduced effectiveness of D1R agonists.
Conversely, A2a receptor activation and D2R inhibition were reported to mediate increased pain sensitivity and behavioral depression associated with sleep deprivation (Sardi et al., 2018) ,
suggesting that increased activity of A2a/D2R-expressing neurons contributes to pain behaviors.
Moreover, the decreased ratio of D1R to A2a receptor-mediated AC activation coupled with reduced post-synaptic D2R expression and activity found in NAc core in the present study suggest that the balance of activity of D1R-versus D2R-expressing medium spiny neurons would be perturbed by neuropathic pain. Predominant activity of A2a-relative to D1R-expressing neurons in NAc core could therefore contribute to pain-induced behavioral depression.
The mechanisms underlying desensitization and/or downregulation of D2R and D1R in NAc core of rats with neuropathy are unclear. A decrease in D2L protein could indicate decreased gene (mRNA) expression, as suggested by prior work on SNI-induced neuropathy (Chang et al., 2014) . However, it is also possible that D2R desensitization and downregulation occur at the post-translational level, for example in response to increased activation by endogenous DA. In fact, increased DA in the NAc has been reported two weeks after SNIinduced neuropathy in rats (Sagheddu et al., 2015) , although decreased DA has also been reported under similar conditions (Wu et al., 2014) . The most common mechanism of G-proteincoupled receptor (including DA receptor) regulation in response to agonist occupancy is receptor phosphorylation followed by b-arrestin-mediated desensitization and internalization (Gurevich et al., 2016) . In addition, D2 receptors interact with G-protein-coupled receptor-associated sorting protein 1 (GASP1), a post-endocytic trafficking protein that promotes trafficking to lysosomes resulting in receptor degradation (Bartlett et al., 2005; Thompson et al., 2010) . This mechanism has been shown to mediate D2R downregulation in response to repeated cocaine treatment.
Therefore, the formalin-induced reduction in D2L receptor protein could have been due to enhanced GASP1-mediated lysosomal degradation of the protein. In contrast, D1R protein was unaffected by formalin treatment, consistent with its lack of interaction with GASP1 (Bartlett et al., 2005; Thompson et al., 2010) . The reduction in D1-like stimulation of AC activity could have been due to receptor phosphorylation and b-arrestin-mediated desensitization. Indeed, D1R
in striatal neurons interact with b-arrestin2 in an agonist-stimulated manner (Macey et al., 2005) , and catechol-containing agonists such as endogenous DA have been shown to effectively recruit b-arrestin2 to the D1R (Gray et al., 2018) .
There are other potential explanations for reduced D1R or D2R signaling in NAc core of formalin-treated rats, including increased heteromeric interactions with other G-protein-coupled receptors. For example, D2R signaling to Gi/o can be reduced by switching to Gs/olf or Gq/11 signaling via heteromomerization with CB1 or A2a receptors, respectively (Ferre et al., 2009 ).
However, no significant differences in CB1 or A2a receptor activity was seen between formalinand saline-treated rats in the present study. Nonetheless, mechanisms including homologous or heterologous receptor regulation and heteromerization are not generally thought to be mutually exclusive, so future studies will be required to tease out the contribution of these molecular processes in DA receptor adaption in neuropathic pain states.
Formalin treatment decreased D2-like agonist potency in intracranial self-stimulation.
Ipl formalin is well-established in preclinical studies as a chronic-pain stimulus (Fu et al., 2001; Grace et al., 2014) , and we reported previously that Ipl formalin served as a chemical neuropathic stimulus that produced a small but significant decrease in ICSS that was sustained for up to 14 days (Leitl and Negus, 2016; Leitl et al., 2014b) . This sustained ICSS depression served as the rationale in the present study to examine dopamine receptor function and expression 14 days after Ipl formalin, however the present study failed to replicate this Ipl formalin-induced ICSS depression. Other treatments that produce neuropathy in rats, such as spinal nerve ligation or chemotherapy administration, are also generally ineffective to decrease ICSS and other forms of positively reinforced operant behavior in rats (Ewan and Martin, 2011; Legakis et al., 2018; Okun et al., 2016) . Taken together, these results suggest that Ipl formalin and other neuropathy manipulations are at best weakly and inconsistently effective to depress ICSS in rats, and results of the present study regarding dopamine receptor function and expression may not be related to pain-related behavioral depression. Factors that underlie the resistance of operant behavior to neuropathic pain-related depression remain to be determined, but it is possible that compensatory increases in mesolimbic dopaminergic activity may have occurred by two-weeks post injury as previously reported using the rat SNI model of neuropathic pain (Sagheddu et al., 2015) . Such an adaptation could potentially underlie both the lack of ICSS depression and the DA receptor desensitization and downregulation observed in NAc core.
Future studies could examine individual differences among subjects in response to neuropathyinducing injury by comparing ICSS responses and function/expression of DA receptors, for example by comparing different strains or using recombinant inbred panels of animals.
Despite the lack of effect on baseline ICSS responding, it remained possible to examine effects of formalin treatment on sensitivity to the effects of D1-like and D2-like receptor agonists.
We reported previously that quinpirole and other D2-like receptor agonists produce dosedependent decreases in ICSS, whereas D1-like agonists produce a mixed profile with stimulation by low doses and primarily depression by high doses (Lazenka et al., 2016) . In the present study, formalin treatment decreased the potency of the D2-like receptor agonist quinpirole to decrease ICSS, which agrees with the decrease in D2R-stimulated G-protein activation seen in the NAc core. However, it is not clear if this effect is mediated by the D2R long or short isoforms or dopamine D3 receptors since both quinpirole and quinelorane can activate all of these receptors. The effectiveness of D2-like receptor agonists to depress ICSS is likely due to decreased DA release through activation of the D2S and dopamine D3 autoreceptors (Gilbert et al., 1995; Khan et al., 1998; Lindgren et al., 2003; Sokoloff et al., 1990; Usiello et al., 2000) .
Decreased expression and signaling of the D2LR may also play a role in decreased ICSS effects of the D2-like agonist, although the potential mechanism is less clear. It is also possible that some of the decrease in D2-like agonist-stimulated G-protein activation in NAc core of formalintreated rats was actually due to decreased signaling of D2s or D3 receptors. In agreement with this interpretation, agonist-stimulated G-protein activation was reduced by 38% in formalinrelative to saline-treated rats, whereas D2LR protein was only reduced by 18%. While this difference in magnitude of effect could be the result of desensitization of a portion of the remaining D2LR, it could also be due to a greater population of D2-family receptors (including D2S and D3) being desensitized.
Despite a decrease in D1R-stimulated AC activity in the NAc core of formalin-treated rats, there was no significant change in D1R expression Moreover, there was no change in the effects of a D1-like agonist on ICSS responding, although the intermediate dose of 0.1 mg/kg SKF82958 generally produced weaker ICSS facilitation in formalin-than saline-treated rats.
One explanation for this lack of effect may be the biphasic nature of D1-like agonist effects on ICSS, making subtle changes difficult to detect. Furthermore, it may be that the reinforcing effects of ICSS are more reliant on D1R expression and function in the NAc shell than core (Cheer et al., 2007) , which would be consistent with our observation of no differences in D1Rstimulated AC activity in the shell. The overall results of these studies indicate that decreased D2-like receptor signaling in the NAc core of formalin-treated rats corresponded with decreased potency to depress ICSS by a D2-like agonist, whereas decreased D1-like receptor signaling in NAc core did not correspond with D1-like agonist effects on ICSS. However, the underlying mechanisms of these behavioral effects are likely to be complex.
Conclusions
In conclusion, this study evaluated DA receptor expression and function in a subset of mesolimbic dopaminergic brain regions associated with motivated behavior in a chemicallyinduced neuropathy model in rats. The findings indicate attenuation of both D1-like and D2-like receptor signaling in the NAc core but not in other regions examined, coupled with a selective reduction in D2LR expression in NAc core. These findings were associated with decreased potency of D2-like but not D1-like agonists to modulate ICSS responding. Moreover, the decreased ratio of D1 to A2a receptor-mediated activation of AC, coupled with downregulated D2R function, could shift the balance of activity to increase that of D2/A2a-expressing relative to D1-expressiong neurons in NAc core. These findings further support the concept that chronic neuropathy can produce lasting perturbations in mesolimbic dopaminergic system function and point to NAc core as a key region in these allostatic adaptations.
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